Overview: NGS Charcot-Marie-Tooth Panel Sequencing TestIntroduction: The NGS Charcot-Marie-Tooth Panel Sequencing Test sequences CMT-related genes to diagnose neuropathy, causing numbness or weakness. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Charcot-Marie-Tooth (CMT) disease.
Other Names: CMT NGS Assay, CMT Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: CMT sequencing began in the 1990s with neuropathy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences CMT-related genes to diagnose neuropathy, guides treatment, and evaluates patients with numbness or weakness.
Test Parameters: 1. CMT Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of numbness, weakness, or CMT symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document numbness, weakness, foot deformities, or family history of CMT. Include current medications, especially pain relievers.
Consent: Written consent required, detailing the tests purpose, CMT implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze CMT genes (e.g., PMP22, GJB1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for CMT diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm CMT, guiding supportive care or genetic counseling. Negative results may require nerve conduction studies.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Nerve conduction studies, EMG, or nerve biopsy to confirm CMT diagnosis.
Test Limitations: Not all CMT cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN CMT Guidelines, 2023; Neurology, Reilly MM, 2022.
